Clinical Trials for Non-Small Cell Lung Cancer

A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the combination of alirocumab, a PCSK9 inhibitor, with cemiplimab, a PD-1 inhibitor, in patients with metastatic non-small cell lung cancer who have progressed after prior PD-1 therapies. It is aimed at those with specific molecular alterations such as EGFR, ALK, and ROS1, following progression on targeted treatments.

ClinicalTrials.gov ID: NCT05553834

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression of 1% to 49%

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial compares the first-line treatment of stage IV or recurrent non-squamous non-small cell lung cancer in patients with PD-L1 expression of 1% to 49%, using Nivolumab and Relatlimab (a LAG-3 inhibitor) with chemotherapy versus Pembrolizumab with chemotherapy.

ClinicalTrials.gov ID: NCT06561386

LUNG-IST-127: A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab (CP) for Patients With Metastatic sqNSCLC With Disease Control Following Induction Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with metastatic squamous non-small cell lung cancer who have achieved disease control after induction therapy, and evaluates the maintenance treatment effect of cabozantinib, a multi-receptor tyrosine kinase inhibitor, plus pembrolizumab, a PD-1 checkpoint inhibitor.

ClinicalTrials.gov ID: NCT05613413

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is for adult patients with advanced MTAP-null solid tumors, evaluating the safety and efficacy of the investigational drug AMG 193, an oral MTA-cooperative PRMT5 inhibitor, alone and in combination with the chemotherapy agent docetaxel. Participants must have a performance status of 0 to 1 and meet specific health criteria.

ClinicalTrials.gov ID: NCT05094336

A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adult patients with advanced non-squamous NSCLC, Stage IV or recurrent, who have failed first-line checkpoint inhibitor therapy, and involves treatment with intravenous atezolizumab, a PD-L1 inhibitor, alongside tocilizumab, an IL-6 receptor antibody, administered every 21 days.

ClinicalTrials.gov ID: NCT04691817

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial evaluates the addition of oral restorative microbiota therapy (RMT) to standard chemotherapy (cisplatin/pemetrexed or carboplatin/pemetrexed) and durvalumab, a PD-L1 targeting monoclonal antibody, in untreated patients with advanced or metastatic adenocarcinoma NSCLC, excluding those with EGFR or ALK mutations.

ClinicalTrials.gov ID: NCT04105270

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial involves treatment-naïve patients with stage IV NSCLC, testing pembrolizumab alone or in combination with chemotherapy and investigational agents like vibostolimab, boserolimab, MK-4830, MK-0482, I-DXd, and HER3-DXd, which target immune checkpoints, PD-1, HER3, and cancer evasion mechanisms to enhance anti-tumor responses.

ClinicalTrials.gov ID: NCT04165070

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in adult patients with advanced or metastatic non-small cell lung cancer (NSCLC), including those experienced with checkpoint inhibitors, focusing on safety, pharmacokinetics, and efficacy measures.

ClinicalTrials.gov ID: NCT04995523

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the combination of atezolizumab, a PD-L1 inhibitor that reactivates anticancer immune responses, with pirfenidone in adult patients with stage 4 NSCLC lacking actionable mutations who have progressed after PD-1/PD-L1 inhibitor therapy, with or without prior chemotherapy. Eligible patients must have a performance status of ECOG 0-2 and adequate organ function, while exclusions apply to those with severe uncontrolled conditions or active auto-immune diseases.

ClinicalTrials.gov ID: NCT04467723

Transarterial Chemoembolization for the Treatment of Lung Cancer and Lung Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the use of transarterial chemoembolization (TACE) with mitomycin, Lipiodol, and Embospheres in adult patients with chemorefractory, unresectable, and unablatable non-small cell lung cancer or lung metastases predominantly in the chest.

ClinicalTrials.gov ID: NCT05672108